Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16945625 | 0.85 | CHRM2 (0.33) | CHRM2KRASCRHR1HSD11B1 | |
| SCHEMBL19033003 | 0.84 | CHRM2 (0.33) | CHRM2KRASCRHR1HSD11B1 | |
| SCHEMBL15998536 | 0.75 | CHRM2 (0.37) | CHRM2KRASCRHR1HSD11B1 | |
| SCHEMBL16945626 | 0.75 | SPHK2 (0.46) | — | |
| SCHEMBL12258771 | 0.71 | HSD11B1 (0.36) | CHRM2KRASCRHR1HSD11B1 | |
| SCHEMBL12888955 | 0.71 | CHRM2 (0.35) | CHRM2KRASCRHR1HSD11B1 | |
| SCHEMBL12904914 | 0.71 | CHRM2 (0.35) | CHRM2KRASCRHR1HSD11B1 | |
| SCHEMBL13105097 | 0.68 | CHRM2 (0.41) | CHRM2KRASHSD11B1 | |
| SCHEMBL14942714 | 0.67 | CHRM2 (0.39) | CHRM2KRASHSD11B1 | |
| SCHEMBL12259635 | 0.67 | CHRM2 (0.39) | CHRM2KRASHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688668-B2 | Long chain base sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-07-30 | — | — | US | disclosed |
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, SGPL1 | CHRM2 4640/4885KRAS 830/4885CRHR1 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.